<p>Lanjewar S, Patil P, <strong>Fineberg S. </strong>Pathologic reporting practices for breast cancer specimens after neoadjuvant chemotherapy- A survey of pathologists in academic institutions across the United States. Modern Pathol. 2019 .(33), 91-98. <a title="Read article" href="https://doi.org/10.1038/s41379-019-0326-5" target="_blank">https://doi.org/10.1038/s41379-019-0326-5</a></p>
<p>Kimberly J. Van Zee, MS, MD, Emily C. Zabor, MS, Rosemarie Di Donato, MD3, Bryan Harmon, MD, Jana Fox, MD, Monica Morrow, MD, Hiram S. Cody III, MD, <strong>Susan A. Fineberg, MD. </strong>A Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Vs Refined Oncotype DX Breast DCIS Score. Annals of Sugical Oncology . 2019 (26), 212-213. <a title="Read article" href="https://doi.org/10.1245/s10434-019-07537-4" target="_blank">https://doi.org/10.1245/s10434-019-07537-4</a></p>
<p>Didonato R, Shapiro N, Koenigsberg, D’Alfonso, T, Jaffer S, <strong>Fineberg S</strong>. Invasive Mucinous Carcinoma of the breast and Response Patterns After Neodjuvant Chemotherapy. Histopathology 2018 May; 72(6):965-973</p>
<p>Hazan, R, Suyamaa, K, Yao J, Liang H, Bernard , Loudig O Amgalm D, Mckimplson W, Phillops G, Segall J, Wang Y, <strong>Fineberg S,</strong> Norton L, Kitsis R. A paradoxical role for an Akt3 splice variant lacking serine 472 phosphorylation site in promoting apoptosis leading to suppression of mammary tumorigenesis. Cancer Research. 2018:78(1).103-114</p>
<p>Pearlman A, Upadhyay K, Cole K, Loke J, Suan K, <strong>Fineberg S,</strong> Freedland S, Shao Y, Ostrer H. Robust genomic copy number predictor of pan cancer metastasis. Genes and Cancer. 2018 <a title="Read article" href="https://doi.org/10.18632/genesandcancer.165" target="_blank">https://doi.org/10.18632/genesandcancer.165</a></p>
<p>Guo Tianhua, Shapiro Nella, Wang Yihong, <strong>Fineberg Susan</strong>. Pleomorphic lobular carcinoma in situ diagnosed by breast core biopsy: Clinicopathologic features and correlation with subsequent excision.Clinical Breast Cancer 2018 (4) e449-454 DOI: /10.1016/j.clbc.2017.10.004</p>
<p>Mclemore L Janakiram M, Albanese J, Shapiro N, Lo Y, Zang X, <strong>Fineberg S.</strong> An immunoscore using PD-L1, CD68 and tumor infiltrating lymphocytes (TILs) to predict response to neoadjuvant chemotherapy in invasive breast cancer. Appl Immunohistochem Mol Morphol.2018;26(9), 611-619. doi: 10.1097/PAI.0000000000000485</p>
<p>Maria-Vittoria Dieci, Nina Radosevic-Robin, <strong>Susan Fineberg</strong> et. al., on behalf of the International Immuno-Oncology Bio-marker Working Group* Update on Tumor Infiltrating Lymphocytes (TILs) in Breast Cancer, including recommendations to assess TILs in Residual Disease and DCIS: a report of the International Immuno-Oncology Biomarker Working group on Breast Cancer*. Seminars in Cancer Biology 2107:52.16-25. <a title="Persistent link using digital object identifier" href="https://doi.org/10.1016/j.semcancer.2017.10.003" target="_blank">https://doi.org/10.1016/j.semcancer.2017.10.003</a></p>
<p>Mantilla JG, Koenigsberg T, Reig B, Shapiro N, Villaneuva-Siles E, <strong>Fineberg S.</strong> Core biopsy of vascular neoplasms of the breast; Pathologic features , imaging and clinical findings. Amer J of Surg Pathol .2016; 40:1424-1434</p>
<p>Polley M, Leung S, Gao D, Mastropasqua M, Zabaglo L, Bartlett J, McShane L, Enos R, Badve S, Bane A, Borgquist S, <strong>Fineberg S</strong>, Lin M, Grabau A, Gutierrez C, Hugh J, Moriya T, Ohi Y, Osborne K, Penault-Llorca F, Piper T, Porter P, Sakatani T, Salgado R, Starczynski J, Lænkholm A, Viale G, Dowsett M, Hayes D, Nielsen T, on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG). An international study to increase concordance in Ki67 scoring. Modern Pathology .2015; 28 (6) :778. PubMed [citation] PMID 25698062</p>
<p>Diaz J, Stead L, Shapiro N, Newell R, Loudig O, Lo Y, Sparano J, <strong>Fineberg S</strong>. Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease. Breast Cancer Research and Treatment. 2013; 138 :91-97. PubMed [citation] PMID 23417359</p>
<p>Giricz, O, Reynolds P, Rammuauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro, N <strong>, Fineberg S,</strong> Kenny P, Loudig O. Has-miR375 is differentially expressed during lobular neoplasia and promotes loss of mammary acinar polarity. Journal of Pathology. 2012; 226 (1): 108-119 .PubMed [citation] PMID 21953071</p>
<p>Auerbach J, Kim M, <strong>Fineberg S</strong>. Can results of routine pathologic evaluation of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX Assay Recurrence Score result? Archives of Pathology and Laboratory Medicine. 2010; 134, (11): 1697-1701. PubMed [citation] PMID 21043825</p>
<p>Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, deng HF, Ament PS, <strong>Fineberg S,</strong> Pestell RG, Carasco N. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nature Medicine .2000; 6 (8): 871-878. PubMed [citation] PMID: 10932223</p>
<p>Casey M, Zimmerman J, Rosenblatt R, <strong>Fineberg S.</strong> Mastectomy without malignancy following carcinoma diagnosed by large core stereotactic breast biopsy. Modern Pathology.1997; 10 (12): 1209-1213. PubMed [citation] PMID: 9436965</p>
<p><strong>Fineberg S</strong>, Rosen P. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol. 1994; 102 (6): 757-762. PubMed [citation] PMID: 7801888</p>
